These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29762872)

  • 21. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
    Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA.
    Martínez-Pías E; Guerrero ÁL; Sierra Á; Trigo J; García-Azorín D
    Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34205832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for migraine with aura.
    Li D; Christensen AF; Olesen J
    Cephalalgia; 2015 Aug; 35(9):748-56. PubMed ID: 25424707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype.
    Hansen JM; Thomsen LL; Olesen J; Ashina M
    Neurology; 2008 Sep; 71(11):841-7. PubMed ID: 18779512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botox treatment for migraine and chronic daily headache in adolescents.
    Chan VW; McCabe EJ; MacGregor DL
    J Neurosci Nurs; 2009 Oct; 41(5):235-43. PubMed ID: 19835236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine.
    Hansen JM; Thomsen LL; Olesen J; Ashina M
    Headache; 2011 Apr; 51(4):544-53. PubMed ID: 21457239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Attack and Clinical Presentation of Hemiplegic Migraine in Pediatric Age: A Multicenter Retrospective Study and Literature Review.
    Toldo I; Brunello F; Morao V; Perissinotto E; Valeriani M; Pruna D; Tozzi E; Moscano F; Farello G; Frusciante R; Carotenuto M; Lisotto C; Ruffatti S; Maggioni F; Termine C; Di Rosa G; Nosadini M; Sartori S; Battistella PA
    Front Neurol; 2019; 10():1079. PubMed ID: 31681150
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
    Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
    Binder WJ; Brin MF; Blitzer A; Schoenrock LD; Pogoda JM
    Otolaryngol Head Neck Surg; 2000 Dec; 123(6):669-76. PubMed ID: 11112955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
    Winner PK; Blumenfeld AM; Eross EJ; Orejudos AC; Mirjah DL; Adams AM; Brin MF
    Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
    Lyseng-Williamson KA; Frampton JE
    CNS Drugs; 2012 Aug; 26(8):717-23. PubMed ID: 22784019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine.
    Kaube H; Herzog J; Käufer T; Dichgans M; Diener HC
    Neurology; 2000 Jul; 55(1):139-41. PubMed ID: 10891926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OnabotulinumtoxinA in pediatric chronic daily headache.
    Kabbouche M; O'Brien H; Hershey AD
    Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.
    Burstein R; Blumenfeld AM; Silberstein SD; Manack Adams A; Brin MF
    Headache; 2020 Jul; 60(7):1259-1272. PubMed ID: 32602955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.